Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Everyday Health and Yahoo Finance. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 56d ago.
Quick answers
Why is "Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Retatrutide Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds Everyday Health · 63d ago
- Another win for Lilly’s triple-g agonist in two more Phase III trials Yahoo Finance · 63d ago
Topics
Related trends
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly is breaking ground in Houston on a facility planned for 2030
Eli Lilly plans a 2030 groundbreaking in Houston as weight-loss drug developers line up to tap a lucrative and increasingly competitive market.
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.